RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
   Small Cell Carcinoma
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
International Early Lung Cancer Action Project (I-ELCAP) Lung Channel

subscribe to Lung newsletter
Latest Research : Cancer : Lung

   EMAIL   |   PRINT
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening

Oct 26, 2006 - 7:24:00 PM , Reviewed by: Rashmi Yadav
"We believe this study provides compelling evidence that CT screening for lung cancer offers new hope for millions of people at risk for this disease and could dramatically reverse lung cancer death rates"

 
[RxPG] Lung cancer can be detected at its very earliest stage in 85 percent of patients using annual low-dose CT screening, and when followed by prompt surgical removal, the 10-year survival rate is 92 percent. These results, to be reported in the October 26 New England Journal of Medicine, would dramatically decrease the number of deaths from lung cancer — the number one cause of cancer deaths among both men and women in the U.S.

The study was launched by a team of researchers at New York-Presbyterian Hospital/Weill Cornell Medical Center in 1993 and has expanded into an international collaboration of 38 institutions in 7 countries, the International Early Lung Cancer Action Project (I-ELCAP). The I-ELCAP study is the largest, long-term study to determine the usefulness of annual screening by CT.

Stage I lung cancer is the only stage at which cure by surgery is highly likely. While survival rates have been climbing for other forms of cancer, the survival rates for lung cancer have remained dismal. Approximately 95 percent of the 173,000 people diagnosed each year die from the disease — more than breast, prostate and colon cancer combined. The high death rates are a consequence of lung cancer not being detected early enough for treatment to be curative.
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening

Among the 31,567 people in the study, CT screening detected 484 people who were diagnosed with lung cancer, 412 of whom were Stage I. Of the Stage I patients who chose not to be treated, all died within five years. Overall, the estimated 10-year survival rate for the 484 participants with lung cancer was 80 percent. The participants were 40 years of age and older and at risk for lung cancer because of a history of cigarette smoking, occupational exposure (to asbestos, beryllium, uranium or radon), or exposure to secondhand smoke.

"We believe this study provides compelling evidence that CT screening for lung cancer offers new hope for millions of people at risk for this disease and could dramatically reverse lung cancer death rates," said Dr. Claudia Henschke, the study's lead author and principal investigator who is chief of the chest imaging division at NewYork-Presbyterian/Weill Cornell and professor of radiology and cardiothoracic surgery at Weill Cornell Medical College.

Since the early 1990s, there have been remarkable advances in CT scanners. Sub-millimeter "slicing" can now be applied to the entire chest in a single breath-hold. As a result, lung cancer may be detected when it is smaller than it was possible to diagnose previously. Although CT scans once yielded only 30 images, current technology yields over 600 images. As the technology advanced, the approaches for studying the usefulness of this technology have also advanced.

The charge for a low-dose CT screening varies, but ranges from $200 to $300. Treatment for Stage I lung cancer is less than half the cost of late-stage treatment. Estimates of the cost-effectiveness of CT screening for lung cancer are similar or better than those for mammography screening for breast cancer.



Publication: October 26 New England Journal of Medicine
On the web: www.med.cornell.edu 

Advertise in this space for $10 per month. Contact us today.


Related Lung News
Tamoxifen reduces mortality rate in lung cancer
Lung Cancer risk greater in tuberculosis patients
Genes to identify patients who would benefit from chemotherapy
First-line treatment with erlotinib improved progression-free survival in advanced lung cancer
Genetic variation-Lung cancer drugs work better in the Japanese than in the Americans
Ireland Cancer Center researchers advance lung cancer treatment
Lung cancer screening regimen provides opportunity for cure
MEK inhibitors may be beneficial for lung cancer containing mutations in the BRaf gene
Potential solution to cetuximab-resistance in lung cancers
Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis

Subscribe to Lung Newsletter

Enter your email address:


 Additional information about the news article
Members of the study's writing committee were New York-Presbyterian/Weill Cornell's Drs. David F. Yankelevitz (attending radiologist and professor of radiology and cardiothoracic surgery at Weill Cornell Medical College), Daniel Libby (attending pulmonologist and professor of pulmonary and critical care medicine at Weill Cornell), James P. Smith (attending pulmonologist and professor of pulmonary and critical care medicine), Mark Pasmantier (attending oncologist and professor of medicine), and Olli S. Miettinen (epidemiologist and professor of medicine).

Also contributing to the study at New York-Presbyterian/Weill Cornell were Drs. Nasser Altorki (director of thoracic surgery and professor of cardiothoracic surgery at Weill Cornell Medical College), Dorothy I. McCauley (attending radiologist and professor of radiology at Weill Cornell), Madeline Vazquez (attending pathologist and professor of pathology), Ali Farooqi (radiology fellow), and at Cornell University in Ithaca, Anthony Reeves (professor of electrical and computer engineering).

Additionally, physician-scientists from New York-Presbyterian Hospital/Columbia University Medical Center participated in the current study: Dr. John H.M. Austin (attending radiologist and professor of radiology at Columbia University College of Physicians and Surgeons) and Dr. Gregory D.N. Pearson (associate attending radiologist and associate professor of radiology at Columbia University College of Physicians and Surgeons).

The current study was supported by numerous private and public grants, including a grant from the National Institutes of Health (NIH).
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)